

IN THE CLAIMS

Please cancel claim 2 without prejudice.

Kindly amend claim 1 as follows:

1 (Amended). A peptide which inhibits T-cell antigen receptor (TCR) function, wherein the peptide is of the following formula:-

R1-X-Z-X-R2 in which

X is a hydrophobic amino acid or a hydrophobic peptide sequence comprising between 2 and 6 amino acids

Z is a charged amino acid

R1 is NH2 and

R2 is COOH.

Kindly amend claim 3 as follows:

3 (Amended). The peptide according to claim 1 wherein at least 50% of the amino acids which make up the hydrophobic peptide sequence are hydrophobic amino acids.

Kindly amend claim 4 as follows:

4 (Amended). The peptide according to claim 1 wherein Z is selected from Arg and Lys.

Kindly amend claim 5 as follows:

5 (Twice Amended). The peptide according to claim 1 which has the formula

NH2-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-Phe-OH (SEQ ID NO. 6),

NH2-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-OH (SEQ ID NO. 7),

NH2-Leu-Arg-Ile-Leu-Leu-Leu-Gly-Val-OH (SEQ ID NO. 8),

NH2-Leu-Gly-Ile-Leu-Leu-Leu-Lys-Val-OH (SEQ ID NO. 9),

B²
NH₂-Ile-Leu-Leu-Gly-Lys-Ala-Thr-Leu-Tyr-OH (SEQ ID NO. 10),

NH₂-Met-Gly-Leu-Arg-Ile-Leu-Leu-Leu-OH (SEQ ID NO. 11), or

NH₂-Leu-Leu-Met-Thr-Leu-Arg-Leu-Trp-Ser-Ser-COOH (SEQ ID NO. 12).

(Kindly amend claim 6 as follows:)

6 (Amended). The peptide according to claim 1 wherein Z is selected from aspartic acid and glutamic acid.

Kindly amend claim 8 as follows:

B³
8 (Amended). A peptide which inhibits TCR function, wherein the peptide is derived from the TCR- α intracellular chain and comprises the formula:

NH₂-Ala-Gly-Phe-Asn-Leu-Leu-Met-Thr-COOH (SEQ ID NO. 16).

Kindly amend claim 12 as follows:

12 (Twice Amended). A peptide which inhibits T-Cell antigen receptor function wherein the peptide has the formula:

NH₂-Tyr-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 17), or

NH₂-Trp-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 18), or

B⁴
NH₂-Tyr-Gly-Arg-Ala-Asp-Cys-Ile-Thr-Ser-OH (SEQ ID NO. 19), or

NH₂-Ser-Ser-Asp-Val-Pro-Cys-Asp-Ala-Thr-Leu-Thr-OH (SEQ ID NO. 20).

(Kindly amend claim 13 as follows:)

13 (Amended). A therapeutic composition active against disorders in which T-cells are involved or recruited comprising a peptide as claimed in claim 1 and a pharmaceutically acceptable carrier.